---
title: "688767.SH (688767.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688767.SH/news.md"
symbol: "688767.SH"
name: "688767.SH"
parent: "https://longbridge.com/en/quote/688767.SH.md"
datetime: "2026-05-20T01:33:23.292Z"
locales:
  - [en](https://longbridge.com/en/quote/688767.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688767.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688767.SH/news.md)
---

# 688767.SH (688767.SH) — Related News

### [Conference Guide + Full Schedule Released | CGCS2026 The 7th International Cell and Gene Therapy China Summit and Exhibition invites you to meet in Suzhou on May 28](https://longbridge.com/en/news/285661402.md)
*2026-05-08T04:02:37.000Z*
> The 7th International Cell and Gene Therapy China Summit and Exhibition (CGCS 2026) will be held on May 28-29, 2026, at 

### [Shenbi Biotechnology has completed tens of millions of yuan in Pre-A round financing](https://longbridge.com/en/news/285483547.md)
*2026-05-07T04:26:44.000Z*
> On May 7th, according to Bailian Zhigao, Shenbi Biotechnology has completed tens of millions of yuan in Pre-A round fina

### [Guotai Junan Securities: Innovation is Key in the Post-Procurement Era, Focus on Investment Opportunities in Domestic New Drugs](https://longbridge.com/en/news/284290232.md)
*2026-04-28T01:23:17.000Z*
> Guojin Securities released a research report indicating that under the normalization of centralized procurement, domesti

### [New Stock News | Zhitai Biotechnology submits application to Hong Kong Stock Exchange](https://longbridge.com/en/news/284066568.md)
*2026-04-25T02:17:04.000Z*
> According to the Hong Kong Stock Exchange, on April 24, 2026, Beijing Zhitai Biopharmaceutical Technology Co., Ltd. (Zhi

### [BIOTEST BIOTECH: Net profit in 2025 is expected to decrease by 70.94% year-on-year, proposing a dividend of 7 yuan per 10 shares](https://longbridge.com/en/news/283990556.md)
*2026-04-24T11:22:54.000Z*
> On April 24th, BIOTEST BIOTECH released its annual report, expecting a revenue of 448 million yuan in 2025, a year-on-ye

### [BIOTEST BIOTECH: Net loss of 10.2079 million yuan in the first quarter of 2026](https://longbridge.com/en/news/283987129.md)
*2026-04-24T11:04:39.000Z*
> BIOTEST BIOTECH announced that its operating revenue in the first quarter of 2026 was 89.3767 million yuan, a year-on-ye

### [As the "Order No. 818" is about to be implemented, how will strict policy regulation reshape the cell therapy industry?](https://longbridge.com/en/news/283439318.md)
*2026-04-21T04:44:13.000Z*
> The "Regulations on the Management of Clinical Research and Clinical Translational Applications of Biomedical New Techno

### [The world's number one market share but has suffered losses for three consecutive years, Leading Bio is trapped in a situation of "selling more but losing more."](https://longbridge.com/en/news/283288843.md)
*2026-04-20T03:30:41.000Z*
> Yinhang Biotechnology, the world's leading synthetic biology company by market share, is facing a dilemma of continuous 

### [BIOTEST BIOTECH plans to repurchase shares for 100 million to 200 million yuan](https://longbridge.com/en/news/282158658.md)
*2026-04-09T08:22:11.000Z*
> According to the Zhitong Finance APP, BIOTEST BIOTECH announced that the company plans to repurchase shares for 100 mill